Garland Jonathan Todd
Known title: Chief Commercial OfficerCIK: 0001924824
Associated companies
Transaction History
| CTKB | ▲ Buy | Option Exercise | 1,951 | — | 8/18/2023 | View on chart |
| CTKB | ▲ Buy | Option Exercise | 2,761 | — | 8/18/2023 | View on chart |
| CTKB | ▼ Sell | Tax Withholding | 760 | $6K | 8/18/2023 | View on chart |
| CTKB | ▼ Sell | Tax Withholding | 1,076 | $9K | 8/18/2023 | View on chart |
| CTKB | ▲ Buy | Option Exercise | 7,804 | — | 5/18/2023 | View on chart |
| CTKB | ▼ Sell | Tax Withholding | 3,040 | $20K | 5/18/2023 | View on chart |
| CTKB | ▲ Buy | Option Exercise | 1,840 | — | 5/18/2023 | View on chart |
| CTKB | ▼ Sell | Tax Withholding | 717 | $5K | 5/18/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Cytek spotlights spectral flow cytometry at ESCCA and ICCS conferences
Cytek Biosciences drew attention to the growing use of its spectral flow cytometry technology in clinical research at the ESCCA and ICCS conferences. The company also confirmed it will attend upcoming investor conferences. These are routine participation and awareness events rather than material business updates, with no new financial figures or product announcements disclosed. The current price sits within the stock's 52-week range of $3.28 to $6.18, below the average analyst target of $5.56.
Cytek spotlights spectral flow cytometry at ESCCA and ICCS conferences. Cytek Biosciences drew attention to the growing use of its spectral flow cytometry technology in clinical research at the ESCCA and ICCS conferences. The company also confirmed it will attend upcoming investor conferences. These are routine participation and awareness events rather than material business updates, with no new financial figures or product announcements disclosed. The current price sits within the stock's 52-week range of $3.28 to $6.18, below the average analyst target of $5.56.